Biologics Contract Development & Manufacturing Organization (CDMO) Market Size & Share, by Product Type (Biologics, Biosimilars); Cell Line Type (Microbial, Mammalian, Viral Vector & Other Modalities); Service Type (Clinical, Commercial) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5516
  • Published Date: Jan 08, 2024
  • Report Format: PDF, PPT

Companies Dominating the Biologics CDMO Landscape

top-features-companies
    • AGC Biologics
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Biocon Biologics Ltd.
    • Catalent, Inc.
    • Emergent BioSolutions
    • JRS PHARMA LP
    • Lonza Group Ltd.
    • Binex Co., Ltd.
    • Thermo Fisher Scientific Inc.
    • Icon PLC
    • Parexel International Corporation


In-the-news

In The News

  • At its protein biologics manufacturing facility in Seattle, AGC Biologics, a preeminent worldwide Biopharmaceutical Contract Development and Manufacturing Organisation (CDMO), has announced the launch of a new commercial manufacturing project. Provention Bio, Inc., a biopharmaceutical firm dedicated to furthering the development of investigational medicines that may intercept and prevent debilitating and life-threatening immune-mediated disorders, is the source of TZIELD (teplizumab-mzwv), a novel medication for Type 1 Diabetes that the CDMO is creating.
  • Being the first provider of biosimilar insulins to endorse and support the International Diabetes Federation (IDF) and its Core Mission initiative, Biocon Biologics Ltd. is a fully integrated, "pure play" biosimilars firm and a subsidiary of Biocon Ltd. This significant collaboration with IDF advances Biocon Biologics' goal of providing diabetics with accessible, inexpensive insulins on a global scale and aligns with the beginning of the centenary celebrations of insulin invention.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5516
  • Published Date: Jan 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are rising covid19 cases, surge in demand for cell & genetic therapy, and growth in use of biologics in geriatric population.

The market size of biologics CDMO is anticipated to attain a CAGR of 12%over the forecast period, i.e., 2024-2036.

The major players in the market are AGC Biologics, Biocon Biologics Ltd., Catalent, Inc., Emergent BioSolutions and others.

The biologics segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying